ATE68352T1 - Methode zur behandlung der eisenuebersaettigung. - Google Patents

Methode zur behandlung der eisenuebersaettigung.

Info

Publication number: ATE68352T1
Authority: AT; Austria
Prior art keywords: iron; supersaturation; treatment; mammal; red blood
Prior art date: 1986-11-21

Application number

AT87310300T

Other languages

English (en)

Inventor

John William Adamson

Michael Richard Downing

Joseph Wetherill Eschbach

Joan Christine Egrie

Original Assignee

Kirin Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-11-21

Filing date

1987-11-20

Publication date

1991-11-15

1987-11-20 Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc

1991-11-15 Application granted granted Critical

1991-11-15 Publication of ATE68352T1 publication Critical patent/ATE68352T1/de

Links

XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title abstract 6
229910052742 iron Inorganic materials 0.000 title abstract 3
241000124008 Mammalia Species 0.000 abstract 3
210000003743 erythrocyte Anatomy 0.000 abstract 2
102000003951 Erythropoietin Human genes 0.000 abstract 1
108090000394 Erythropoietin Proteins 0.000 abstract 1
206010065973 Iron Overload Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229940105423 erythropoietin Drugs 0.000 abstract 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Treatment Of Water By Oxidation Or Reduction (AREA)
Manufacture Of Iron (AREA)
Chemical Treatment Of Metals (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Treatment Of Water By Ion Exchange (AREA)
Peptides Or Proteins (AREA)
Compounds Of Iron (AREA)
Hydrogen, Water And Hydrids (AREA)

AT87310300T 1986-11-21 1987-11-20 Methode zur behandlung der eisenuebersaettigung. ATE68352T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/933,495 US5013718A (en)	1986-11-21	1986-11-21	Method for treating iron overload using EPO
EP87310300A EP0269394B1 (de)	1986-11-21	1987-11-20	Methode zur Behandlung der Eisenübersättigung

Publications (1)

Publication Number	Publication Date
ATE68352T1 true ATE68352T1 (de)	1991-11-15

Family

ID=25464076

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT87310300T ATE68352T1 (de)	1986-11-21	1987-11-20	Methode zur behandlung der eisenuebersaettigung.

Country Status (16)

Country	Link
US (1)	US5013718A (de)
EP (1)	EP0269394B1 (de)
JP (1)	JPH0692316B2 (de)
KR (1)	KR950009100B1 (de)
AT (1)	ATE68352T1 (de)
AU (1)	AU602028B2 (de)
CA (1)	CA1322165C (de)
DE (1)	DE3773852D1 (de)
DK (1)	DK167650B1 (de)
ES (1)	ES2039252T3 (de)
GR (1)	GR3003254T3 (de)
IE (1)	IE60865B1 (de)
IL (1)	IL84275A (de)
NZ (1)	NZ222432A (de)
PT (1)	PT86187B (de)
WO (1)	WO1988003808A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2858752B2 (ja) *	1987-04-10	1999-02-17	オーソ・フアーマシユーチカル・コーポレーシヨン	正常な哺乳動物のヘマトクリツト値の増大方法
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
US6012450A (en) *	1993-01-29	2000-01-11	Aradigm Corporation	Intrapulmonary delivery of hematopoietic drug
US5354934A (en) *	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin
ES2206521T3 (es)	1994-11-03	2004-05-16	Roche Diagnostics Gmbh	Utilizacion de la eritropoyetina en el tratamiento de artritis reumatoide.
EP0817655B1 (de)	1995-03-31	2004-05-19	Aradigm Corporation	Intrapulmonare verabreichung vom hematopoietischem medikament
TW586933B (en) *	1996-06-20	2004-05-11	Chugai Pharmaceutical Co Ltd	Compositions for treating liver-complaints using EPO
US5952226A (en) *	1996-11-05	1999-09-14	Modex Therapeutiques	Hypoxia responsive EPO producing cells
AR019025A1 (es)	1998-04-09	2001-12-26	Roche Diagnostics Gmbh	Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
EP0965349A1 (de) *	1998-06-18	1999-12-22	Roche Diagnostics GmbH	Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
US6210924B1 (en)	1998-08-11	2001-04-03	Amgen Inc.	Overexpressing cyclin D 1 in a eukaryotic cell line
DE19857609A1 (de) *	1998-12-14	2000-06-15	Hannelore Ehrenreich	Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
AU3269101A (en) *	1999-11-12	2001-06-06	James C. Barton	Diagnostic test for hemochromatosis
US7160855B2 (en) *	2002-03-14	2007-01-09	Children's Hospital & Research Center At Oakland	Enhancement of iron chelation therapy
DE10234192B4 (de)	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Verwendung von Erythropoetin
CA2498319A1 (en) *	2002-09-09	2004-03-18	Nautilus Biotech	Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
EP2120998B1 (de)	2006-11-28	2013-08-07	HanAll Biopharma Co., Ltd.	Modifizierte erythropoetin-polypeptide und ihre verwendungen zur behandlung
US10694962B2 (en)	2011-06-13	2020-06-30	Cedars-Sinai Medical Center	Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
US10694961B2 (en) *	2011-06-13	2020-06-30	Cedaris-Sinai Medical Center	Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
FR3037592B1 (fr)	2015-06-18	2017-06-09	Michelin & Cie	Pneumatique pourvu d'une bande de roulement comprenant un elastomere dienique et un systeme d'elastomeres thermoplastiques
JP2023544727A (ja)	2020-10-02	2023-10-25	ケロスセラピューティクスインコーポレイテッド	アクチビン受容体ｉｉ型バリアントの使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0686480B2 (ja) *	1983-02-21	1994-11-02	雪印乳業株式会社	エリスロポエチン製造用モノクローナル抗体
US4703008A (en) *	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
NZ210501A (en) *	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4667016A (en) *	1985-06-20	1987-05-19	Kirin-Amgen, Inc.	Erythropoietin purification

1986
- 1986-11-21 US US06/933,495 patent/US5013718A/en not_active Expired - Lifetime
1987
- 1987-10-19 WO PCT/US1987/002673 patent/WO1988003808A1/en not_active Ceased
- 1987-10-19 AU AU81794/87A patent/AU602028B2/en not_active Expired
- 1987-10-19 KR KR1019880700864A patent/KR950009100B1/ko not_active Expired - Lifetime
- 1987-10-25 IL IL84275A patent/IL84275A/xx not_active IP Right Cessation
- 1987-11-03 NZ NZ222432A patent/NZ222432A/xx unknown
- 1987-11-18 CA CA000552139A patent/CA1322165C/en not_active Expired - Lifetime
- 1987-11-18 IE IE311387A patent/IE60865B1/en not_active IP Right Cessation
- 1987-11-19 JP JP62293071A patent/JPH0692316B2/ja not_active Expired - Lifetime
- 1987-11-20 PT PT86187A patent/PT86187B/pt active IP Right Revival
- 1987-11-20 EP EP87310300A patent/EP0269394B1/de not_active Expired - Lifetime
- 1987-11-20 ES ES198787310300T patent/ES2039252T3/es not_active Expired - Lifetime
- 1987-11-20 DE DE8787310300T patent/DE3773852D1/de not_active Expired - Lifetime
- 1987-11-20 AT AT87310300T patent/ATE68352T1/de not_active IP Right Cessation
1988
- 1988-07-21 DK DK407488A patent/DK167650B1/da not_active IP Right Cessation
1991
- 1991-12-02 GR GR91401882T patent/GR3003254T3/el unknown

Also Published As

Publication number	Publication date
CA1322165C (en)	1993-09-14
KR890700032A (ko)	1989-03-02
DK407488D0 (da)	1988-07-21
GR3003254T3 (en)	1993-02-17
EP0269394B1 (de)	1991-10-16
IL84275A (en)	1993-04-04
IE873113L (en)	1988-05-21
AU602028B2 (en)	1990-09-27
PT86187A (en)	1987-12-01
PT86187B (pt)	1990-11-07
EP0269394A3 (en)	1988-09-14
KR950009100B1 (ko)	1995-08-14
JPS63159322A (ja)	1988-07-02
DK167650B1 (da)	1993-12-06
AU8179487A (en)	1988-06-16
IE60865B1 (en)	1994-08-24
WO1988003808A1 (en)	1988-06-02
US5013718A (en)	1991-05-07
EP0269394A2 (de)	1988-06-01
DK407488A (da)	1988-07-21
DE3773852D1 (de)	1991-11-21
NZ222432A (en)	1990-07-26
JPH0692316B2 (ja)	1994-11-16
ES2039252T3 (es)	1993-09-16

Similar Documents

Publication	Publication Date	Title
DE3773852D1 (de)	1991-11-21	Methode zur behandlung der eisenuebersaettigung.
PT87086A (pt)	1988-04-01	Active specific immune suppression
NO880929L (no)	1988-03-02	Produksjon og bruk av il-6.
NO880022L (no)	1988-01-05	Fremstilling av m-csf.
PT87335A (pt)	1988-05-01	A simplified method for the preparation of human lymphokine activated killer cells
BG47497A3 (en)	1990-07-16	Method for preparing of (l)- alpha- ethyl- 2- oxo- 1- pyrolidineacetamide
EP0179390A3 (de)	1987-07-29	L-Lysin- und L-Histidinpyruvat
FR2591892B1 (fr)	1988-09-16	Association collagene/principe actifantiseptique et/ou anti-inflammatoire a titre de composition, son procede de preparation et son utilisation pour la fabrication d'une composition pharmaceutique
ES480535A1 (es)	1979-11-16	Procedimiento mejorado para la preparacion de interferon.
PT87197A (pt)	1988-05-01	Processo para preparacao de agentes terapeuticos eritropoietina
FR2559781B3 (fr)	1986-05-30	Nouveau vecteur plasmidique hybride de e. coli conferant le pouvoir de faire fermenter le saccharose et son procede de preparation
ATA147676A (de)	1978-01-15	Verfahren zur herstellung von reiner traubensaure und von mesoweinsaure
OA09455A (fr)	1992-11-15	Nouveaux polyols furanniques, utilisation de ceux-ci comme polyols dans la formation de polyuréthannes, polyuréthannes ainsi obtenus et leur procédé de préparation.
JPS52156840A (en)	1977-12-27	Sulfonic acid esters of optically active allethrolone* process for manufacture thereof and use thereof to inversion of allethrolone at asymmetric center
ES8302016A1 (es)	1983-01-01	Procedimiento para tratar fracciones individuales de plasma sanguineo.
SE429091B (sv)	1983-08-15	Forfarande for behandling av cellprotein for att reducera halten nukleinsyra i cellerna
DK299585D0 (da)	1985-07-02	Fremgangsmaade til behandling af syreholdige afgangsgasser
DE69011870D1 (de)	1994-09-29	Verfahren und zubereitung für die behandlung von hiv-infizierten säugetieren.
PH23658A (en)	1989-09-27	Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor
FR2558481B1 (fr)	1988-11-04	Procede de preparation de l'acide 4-amino-3-hydroxybutyrique optiquement actif
IT8509310A0 (it)	1985-01-17	Metodo rapido di prova per determinare la sedimentazione del sangue venoso
FR2549390B1 (fr)	1988-05-20	Procede de retention d'un corps dissous dans une solution
SU584001A1 (ru)	1977-12-15	Способ регенерации этилендиаминтетрауксусной кислоты и меди их меднотрилоновых растворов
FR2616430B1 (fr)	1990-01-12	Nouveaux diesters de l'acide azelaique, leur procede de preparation, les compositions topiques les contenant et leur utilisation dans le traitement de l'acne
ES457992A1 (es)	1978-07-16	Un procedimiento para preparar nuevas sales por adicion de acido del d-(+)-1-(3-hidroxifenil)-2-aminopropano.

Legal Events

Date	Code	Title	Description
1992-07-15	UEP	Publication of translation of european patent specification
2008-02-15	EELA	Cancelled due to lapse of time